Pharma & Biotech Events & Conferences
Refine Search
Pharmaceutical
Germany’s Merck KGaA has announced new interim data for its multiple sclerosis (MS) treatment Mavenclad (cladribine). 13 October 2021
Biotechnology
In multiple sclerosis (MS), new data for Ocrevus (ocrelizumab) should help physicians understand the long-term characteristics of treatment with the monoclonal antibody. 13 October 2021
Biotechnology
Dutch antibody-drug conjugate (ADC) specialist Synaffix today presented new data regarding its topoisomerase 1 inhibitor linker-payload based on exatecan (SYNtecan E), at the World ADC Conference, showing excellent in vivo efficacy and tolerability. 13 October 2021
Pharmaceutical
Tolebrutinib, an investigational oral Bruton’s tyrosine kinase (BTK) inhibitor under development by Sanofi, has shown favorable levels of tolerability in a Phase IIb trial. 13 October 2021
Pharmaceutical
Fortress Biotech subsidiary Cyprium Therapeutics, with support from its licensing partner Sentynl Therapeutics, which is wholly-owned by India’s Cadila Healthcare, today announced positive results from an efficacy and safety analysis of data integrated from two completed pivotal studies in patients with Menkes disease treated with CUTX-101, copper histidinate (CuHis). 8 October 2021
Biotechnology
Johnson & Johnson has announced a new analysis of Stelara (ustekinumab), using safety data from 13 clinical studies across approved indications. 6 October 2021
Biotechnology
US biotech Incyte has announced the full 24-week results from its pivotal Phase III TRuE-V clinical trial program investigating Opzelura (ruxolitinib) cream, a topical JAK inhibitor, in adolescent and adult patients (age ≥12 years) with nonsegmental vitiligo. 4 October 2021
Biotechnology
Danish dermatology specialist LEO Pharma today announced results showing that after two years of continuous treatment with Adtralza (tralokinumab), adult patients with moderate-to-severe atopic dermatitis maintained improvements in signs and symptoms, itch severity and sleep interference. 30 September 2021
Biotechnology
Positive results from a Phase IIa study evaluating the safety and efficacy of amlitelimab (formerly KY1005), a human monoclonal antibody targeting key immune system regulator OX40-Ligand, were presented as a late-breaker today at the European Academy of Dermatology and Venerology (EADV) 2021 Virtual Congress. 30 September 2021
Biotechnology
Swiss independent dermatology specialist Galderma today announced the presentation of new Phase II data supporting the efficacy of its investigational monoclonal antibody, nemolizumab, at the virtual 30th EADV congress now taking place. 29 September 2021
Pharmaceutical
Swiss pharma giant Roche today announced data from across its growing neuromuscular portfolio at the World Muscle Society (WMS) Virtual Congress 20–24 September 2021. 24 September 2021
Pharmaceutical
Otsuka Pharmaceutical company Astex Pharmaceuticals has provided new Phase III data from the ASCERTAIN trial of Inqovi (decitabine/cedazuridine). 24 September 2021
Biotechnology
Boston, USA-based Rhythm Pharmaceuticals has presented new data and analyses from Phase II and III trials of its candidate setmelanotide. 23 September 2021
Biotechnology
Data from the Phase III IMpower010 trial testing Tecentriq (atezolizumab) after surgery and chemo in lung cancer show a 34% reduction in the risk of disease recurrence or death. 21 September 2021
Biotechnology
Bristol Myers Squibb’s immuno-oncology combination of Opdivo (nivolumab) and Yervoy (ipilimumab) continues to deliver mixed results, according to data shared at the European Society for Medical Oncology (ESMO) Congress 2021. 20 September 2021
Biotechnology
US epigenetic therapies company Epizyme has presented new data on its approved product, Tazverik (tazemetostat), at the European Society for Medical Oncology (ESMO) Congress 2021. 20 September 2021
Biotechnology
Positive results from a Phase III trial of OSE Immunotherapeutics’ neoepitope-based cancer vaccine Tedopi (OSE: 2101) lifted shares in the company by 20% on Monday. 20 September 2021
Biotechnology
US oncology specialist Mirati Therapeutics was trading 8% higher in early pre-market trading on Monday after presenting results at the European Society for Medical Oncology (ESMO) Congress 2021. 20 September 2021
Biotechnology
A suite of new data from New Jersey, USA’s Merck & Co will help cement its lead in checkpoint inhibition, with Keytruda (pembrolizumab) the star of the show. 20 September 2021
Biotechnology
Interim data from two cohorts of the Phase Ib/II innovaTV 205 multi-cohort, open-label trial of tisotumab vedotin in recurrent or metastatic cervical cancer were presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2021. 20 September 2021
Biotechnology
Cellular immunotherapy specialist Fate Therapeutics soared as much as 73%, and closed up 12.45 at $2.27 yesterday, after it released early-stage data on its FT819 in lupus. 19 November 2024
Pharmaceutical
US clinical-stage biopharmaceutical company Boston Pharmaceuticals has announced positive results from a Phase II study evaluating the safety and efficacy of once-monthly efimosfermin alfa (formerly known as BOS-580), a long-acting FGF21 analogue, in participants with stage F2/F3 fibrosis due to metabolic dysfunction-associated steatohepatitis (MASH). 18 November 2024
Pharmaceutical
French drugmaker Ipsen today announced the long-term efficacy and safety of patients treated with Bylvay (odevixibat) from two Phase III open-label extension studies. 18 November 2024
Pharmaceutical
US antiviral giant Gilead Sciences on Friday unveiled two-and-a-half-year interim analysis from the ongoing Phase III ASSURE study of its Livdelzi (seladelpar). 16 November 2024
Pharmaceutical
French drugmaker Ipsen announced late-breaking data for Iqirvo (elafibranor 80mg tablets) from an interim analysis of the ongoing open-label extension of the Phase III ELATIVE study at the American Association for the Study of Liver Disease (AASLD) congress. 16 November 2024
Biotechnology
Belgian drugmaker UCB and US biotech Biogen’s Phase III PHOENYCS GO trial results signal a pivotal development for systemic lupus erythematosus (SLE) treatment, as dapirolizumab pegol met its primary endpoint and demonstrated enhanced disease control and safety at Week 48. 13 November 2024
Biotechnology
Syndax Pharmaceuticals has announced that its Phase II AUGMENT-101 trial of experimental drug revumenib achieved its primary endpoint. 13 November 2024
Pharmaceutical
Research results featured heavily in the news last week, first with Viking Therapeutics releasing promising early-stage data for its investigational medicine VK2738 at the ObesityWeek meeting. US biotech Beam Therapeutics released early-stage data on its sickle cell disease candidate BEAM-101. Also of note, Arcus Biosciences and Gilead Sciences announced promising Phase III results for their TIGIT inhibitor domvanalimab in combination with zimberelimab. Denmark’s Novo Nordisk released financial results that attracted interest. 10 November 2024
Biotechnology
Shanghai-based BioCity Biopharma has announced promising late-stage results from the Phase II 2-SUCCEED clinical trial of SC0062. 7 November 2024
Biotechnology
Results from the ARC-10 Phase III study of Arcus Biosciences and Gilead Sciences’ domvanalimab and zimberelimab combination therapy indicate a significant reduction in mortality risk for patients with certain advanced lung cancers. 7 November 2024
Biotechnology
Beam Therapeutics will detail new clinical and preclinical data on its sickle cell disease (SCD) therapies at the upcoming American Society of Hematology (ASH) meeting. 6 November 2024
Pharmaceutical
AstraZeneca has presented early results on three experimental weight-loss drugs at the ObesityWeek conference in San Antonio, showing encouraging signs for its obesity pipeline. 5 November 2024
Pharmaceutical
US neuroscience-focused biopharma Neurocrine Biosciences presented new data from more than 300 patients diagnosed with tardive dyskinesia and treated with Ingrezza (valbenazine) capsules at the 2024 Psych Congress in Boston. 5 November 2024
Pharmaceutical
Viking Therapeutics (Nasdaq: VKTX) reported promising early results for its experimental obesity pill, VK2735, with increased weight loss at higher doses. 4 November 2024
Pharmaceutical
The US subsidiary of Israel’s Teva Pharmaceutical Industries has announced new, positive data on social functioning and quality of life from the Phase III subcutaneous olanzapine extended-release injection study (SOLARIS) trial evaluating TEV-'749 in adult patients diagnosed with schizophrenia. 2 November 2024
Biotechnology
UCB has reported Phase IIa data from the TOGETHER (AH0003) study, investigating the safety, efficacy, and tolerability of bepranemab - an investigational anti-tau antibody targeting the mid-region of the tau protein - in people living with prodromal to mild Alzheimer’s disease. 1 November 2024
Biosimilars
The US unit of South Korea-based biosimilar drug developer Celltrion
has announced a late-breaking post hoc analysis of the pivotal LIBERTY studies (LIBERTY-CD and LIBERTY-UC) of Zymfentra (infliximab-dyyb), during the American College of Gastroenterology (ACG) 2024 Annual Scientific Meeting. 30 October 2024
Biotechnology
US pharma major Eli Lilly has released results from two, multi-year, Phase III studies that showed patients treated with mirikizumab sustained stable, long-term remission across two types of inflammatory bowel diseases (IBD), ulcerative colitis (UC) and Crohn’s disease. 28 October 2024
Biotechnology
California’s Vera Therapeutics has released 96-week follow-up results from its ORIGIN Phase IIb trial of atacicept, targeting IgA nephropathy (IgAN). 28 October 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze